MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
ProQR Therapeutics N.V. Revenue 2011-2026 | PRQR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Quarterly Revenue ProQR Therapeutics N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1.23 M | 239 K | 872 K | 243 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.23 M | 239 K | 647 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Keros Therapeutics
KROS
|
244 M | $ 11.08 | -1.47 % | $ 412 M |  USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 216.97 | -0.5 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 19.25 | 0.1 % | $ 900 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
15.6 M | $ 0.67 | 10.54 % | $ 7.67 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.4 | -0.36 % | $ 357 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
32.2 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.63 | - | $ 16.5 M | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
167 M | $ 199.63 | -0.36 % | $ 3.65 B | USA |
 |
Longeveron
LGVN
|
1.2 M | $ 0.9 | -5.5 % | $ 15.8 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 4.3 | -2.83 % | $ 824 M | Canada |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
200 K | $ 2.65 | -0.38 % | $ 5.08 M | USA |
 |
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Cara Therapeutics
CARA
|
21 M | - | -3.03 % | $ 260 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
868 M | $ 27.05 | -1.99 % | $ 1.56 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |